Kestra Medical Technologies Chief Business Officer Timothy P. Moran Sells $94.4K of Stock
Timothy P. Moran, Chief Business Officer, sold 3,192 shares of Kestra Medical Technologies, Ltd. at $29.56 a share, worth $94.4K in total on Nov 3, 2026. Shares held after the trade: 63,153 (-4.8%).
Kestra Medical Technologies CFO Vaseem Mahboob Sells $2.41M of Stock
Vaseem Mahboob, CFO, sold 79,500 shares of Kestra Medical Technologies, Ltd. at $30.04 to $30.60 a share (average $30.30) in 3 transactions, worth $2.41M in total between Oct 27, 2026 and Oct 29, 2026. Shares held after the trade: 60,609 (-7.3%).
Kestra Medical Technologies Insider Traci S. Umberger Sells $901K of Stock
Traci S. Umberger sold 30,000 shares of Kestra Medical Technologies, Ltd. at $30.03 a share, worth $901K in total on Oct 27, 2026. Shares held after the trade: 195,825 (-13.3%).
Kestra Medical Technologies Insider Traci S. Umberger Sells $2.72M of Stock
Traci S. Umberger sold 100,000 shares of Kestra Medical Technologies, Ltd. at $27.15 to $28.09 a share (average $27.18) in 2 transactions, worth $2.72M in total on Oct 21, 2026. Shares held after the trade: 195,825 (-1.8%).
Kestra Medical Technologies Insider Brian Daniel Webster Sells $443K of Stock
Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies, Ltd. at $29.52 to $29.89 a share (average $29.56) in 2 transactions, worth $443K in total on Oct 20, 2026. Shares held after the trade: 445,215 (-0.4%).
Kestra Medical Technologies Director Raymond W. Cohen Sells $97.5K of Stock
Raymond W. Cohen, Director, sold 3,330 shares of Kestra Medical Technologies, Ltd. at $29.28 a share, worth $97.5K in total on Sep 30, 2026. Shares held after the trade: 54,790 (-5.7%).
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, a 60% increase year-over-year, driven by wearable cardioverter defibrillator (WCD) market expansion and competitive gains. The company reported a GAAP net loss of $44.1 million and increased its full-year fiscal 2027 revenue guidance to $141 million.
Term
Q1 2027
Earnings call
Sep 14, 2026, 4:30 PM ET
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%. We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”